“The Covid-19 vaccine developed by Pfizer and BioNTech produces a robust immune response after just one dose, according to a new Israeli study of vaccinated health care workers at the country’s largest hospital,” as NBC News is reporting.
“The research, published Thursday in the medical journal The Lancet, followed 7,214 staff members at Israel’s Sheba Medical Center, a government-owned facility, who received their first dose of the Pfizer-BioNTech vaccination between Dec. 19 and Jan. 24. Scientists from the medical center found that the vaccine was 85 percent effective at preventing symptomatic Covid-19 within 15 to 28 days after the shot was administered.
“Experts cautioned that more research is needed before broad conclusions can be drawn, but the results do provide some evidence that robust immunity is generated after one dose and that the second dose could be delayed beyond the three weeks prescribed by Pfizer in order to ease distribution and supply constraints.
“The timing of the second dose has been the subject of much recent debate, with some countries such as the United Kingdom opting to delay it as a way to speed up the country’s rate of immunization. In the United States, where the vaccine rollout has been bumpy and winter storms over the past week have hampered some states’ ability to administer shots, similar questions have emerged.”
The rest of the article is here.